Comparative analysis of efficacy and safety of ChAdOx1 nCov-19 and AD26.COV2.S

Abstract

Vaccine technology has been going through some radical and incremental advancement over the years for its importance as the most crucial tool in the prevention and elimination of transmissive diseases. Since the outbreak of COVID-19, several vaccine platforms were being studied, developed, and entered the market. Among the platforms, vector viral vaccines attracted particular attention for the cooperation of viral vectors to deliver genetic material of the pathogens. While the mechanism has improved the flexibility of vaccine design and efficacy, the adverse events after vaccination were worth attention at the same time. Taking ChAdOx12 nCov-19 and AD26.COV2.S. as the subjects, the efficacy and safety of the two vaccine platforms were compared and analyzed. In this paper, the initial vaccine efficacy, the resistances against virus variants, and various post vaccination adverse events were looked in more detail to identify the different factors that could affect the performance of viral vector vaccines.